iTeos Therapeutics Initiates Phase 1/1b Trial with Differentiated Adenosine A2A Antagonist in Patients with Advanced Cancer

World News: . []

“I am tremendously excited to announce that patient dosing in our innovative, adaptive Phase 1/1b trial is now underway with EOS100850, our unique and specific A receptor antagonist. We believe we have a potential best-in-class compound, which was carefully designed with differentiating features to maximize the therapeutic window,”

“The A pathway has emerged as one of the most exciting targets due to the emerging clinical evidence validating the important role adenosine plays in suppressing the immune response to cancer in the tumor microenvironment. EOS100850 addresses the therapeutic challenges found within this tumor microenvironment by achieving a higher degree of receptor inhibition with its PK/PD and non-brain penetrant profile and its ability to maintain potent efficacy despite increased levels of adenosine concentrations. We are optimistic that EOS100850 can restore the immune response and may control cancer for patients in multiple indications.”

For more information on this trial, please visit (Identifier: NCT03873883).

Amber Fennell, Mathew Neal and Sukaina VirjiConsilium Strategic Communications+44 203 709 5700

Sarah McCabe and Carl MauchStern Investor Relations, Inc.+ 1 212 362 1200

More news and information about iTeos Therapeutics SA

Published By:

Globe Newswire: 12:00 GMT Wednesday 17th April 2019

Published: .

Search for other references to "iteos" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us